Verso Biosense signs agreement with hospital
25 March 2021
The Barkby Group PLC
("Barkby", the "Group" or the "Company")
Verso Biosense signs agreement with Homerton University Hospital
The Barbky Group PLC is pleased to announce that Verso Biosense, an innovator in UK femtech focused on improving women's health, has announced the signing of a product collaboration agreement with Homerton University Hospital. Under the agreement, Homerton will utilise Verso's uterine monitoring platform and will collaborate with Verso to help refine the technology and biosensing platform to meet the needs of fertility patients. Verso's platform captures critical in-vivo, biosensing data for optimisation and personalisation of IVF treatment, providing actionable insights for clinicians and patients.
Homerton University Hospital is one of the leading IVF and fertility centres in the UK and is recognised as an innovator in embracing methods and systems that provide better and safer patient care. This includes reviewing and collaborating on novel technologies for the treatment of IVF and fertility.
Charles Dickson, Executive Chairman of Barkby, said:
"I am very excited by this next chapter for Verso Biosense as it partners with some of the UK's leading IVF and fertility centers to refine its technology and biosensing platform with the aim of optimising fertility treatments for millions of women.
"The opportunity in women's health is significant and Verso Biosense's technology has the potential to change diagnostic paradigms across a wide range of further disciplines including endometriosis, fibrosis, menopause and oncology."
Enquiries:
|
The Barkby Group PLC |
|
|
Charles Dickson, Executive Chairman Douglas Benzie, Chief Financial Officer |
|
|
|
|
|
finnCap Ltd (Nomad and Broker) |
+44 (0) 20 7220 0500 |
|
Carl Holmes/Simon Hicks (corporate finance) Tim Redfern/Richard Chambers (ECM)
|
|
|
|
|
|
Camarco (Financial PR) |
+44 (0) 20 3757 4994 |
|
Jennifer Renwick/Jake Thomas
|
|
Notes to editors
The Barkby Group PLC is a diversified group of high growth, high quality businesses run by an entrepreneurial and experienced management team. The existing wholly owned businesses within Barkby include; Commercial Property Development, Barkby Hospitality (comprising Barkby Pubs and Workshop Coffee) and Centurian Automotive Ltd.
In addition to these businesses, Barkby Life Sciences has invested in Verso Biosense, a digital health company aiming to transform Women's Health with precision medicine, and its subsidiary Cambridge Sleep Sciences Ltd has launched, SleepHub™, a device which improves and facilitates natural sleep.
Barkby's strategy is to accelerate and maximise opportunities within its existing businesses as well as continue to source and invest in cash generative, growth businesses with the ability to disrupt.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Judges Scientific
- 1 day ago Mitie Group
- 1 day ago NCC Group
- 1 day ago Worldwide Healthcare Trust
- 1 day ago JpMorgan China Growth & Income